<p>根據公司在最近向證券交易委員會提交的 13F 文件，Synovus Financial Corp 在第四季度將其在 Rocket Pharmaceuticals, Inc.（NASDAQ:RCKT - 免費報告）中的持倉提高了 71.6%。該公司在本季度購買了 68,389 股後，持有 163,893 股這家生物技術公司的股票。到最近一個季度末，Synovus Financial Corp 大約擁有 Rocket Pharmaceuticals 0.18% 的股份，價值 2,060,000 美元。</p>
<p>獲取 <strong>Rocket Pharmaceuticals</strong> 的提醒：</p>
<ul>
<li>3 只准備大幅上漲的小型股</li>
</ul>
<p>其他大型投資者最近也對該公司的持倉進行了調整。Covestor Ltd 在第四季度將其在 Rocket Pharmaceuticals 的股份提高了 33,166.7%。Covestor Ltd 現在擁有 1,996 股這家生物技術公司的股票，價值 25,000 美元，此前在上個季度又購買了 1,990 股。Kennedy Capital Management LLC 在第四季度將其在 Rocket Pharmaceuticals 的股份增加了 222.6%。Kennedy Capital Management LLC 現在擁有 38,208 股這家生物技術公司的股票，價值 480,000 美元，此前在此期間又收購了 26,365 股。Raymond James Financial Inc.在第四季度購買了 Rocket Pharmaceuticals 的新股份，價值 285,000 美元。Renaissance Technologies LLC 在第四季度購買了 Rocket Pharmaceuticals 的新股份，價值 2,747,000 美元。最後，Legal &amp; General Group Plc 在第四季度將其在 Rocket Pharmaceuticals 的股份提高了 3.3%。Legal &amp; General Group Plc 現在擁有 75,454 股這家生物技術公司的股票，價值 948,000 美元，此前在此期間又購買了 2,416 股。98.39% 的股票由機構投資者和對沖基金持有。</p>
<h2>Rocket Pharmaceuticals 股價上漲 10.5%</h2>
<p>NASDAQ:RCKT 週三開盤價為 6.53 美元。Rocket Pharmaceuticals, Inc.的 1 年最低價為 4.55 美元，1 年最高價為 26.98 美元。該公司的債務與股本比率為 0.06，速動比率為 6.05，流動比率為 6.05。該股票的 50 日移動平均價格為 8.19 美元，200 日移動平均價格為 11.92 美元。該股票的市值為 6.9629 億美元，市盈率為-2.37，貝塔係數為 1.00。</p>
<p>Rocket Pharmaceuticals（NASDAQ:RCKT - 獲取免費報告）最近在 3 月 3 日（星期一）發佈了季度財報。這家生物技術公司報告的每股收益為（0.62 美元），超過分析師一致預期的（0.68 美元）0.06 美元。作為一個整體，賣方分析師預計 Rocket Pharmaceuticals, Inc.在當前財年將發佈-2.83 的每股收益。</p>
<h2>Rocket Pharmaceuticals 的內部買賣</h2>
<p>在其他消息中，首席執行官 Gaurav Shah 在 4 月 10 日（星期四）購買了 20,000 股該股票。每股購買價格為 5.08 美元，總價值為 101,600.00 美元。收購完成後，首席執行官現在擁有 792,680 股該公司的股票，價值約為 4,026,814.40 美元。這筆交易代表了他們持股比例的 2.59% 的增加。該收購在向證券交易委員會的文件中披露，相關信息可通過此鏈接獲取。此外，內部人士 Kinnari Patel 在 4 月 9 日（星期三）購買了 21,099 股該公司的股票。每股購買成本為 4.70 美元，總價值為 99,165.30 美元。購買後，該內部人士現在直接擁有 26,774 股該公司股票，價值約為 125,837.80 美元。這筆交易使他們的持股比例增加了 371.79%。該購買的披露信息可以在這裏找到。目前 28.50% 的股票由公司內部人士持有。</p>
<h2>分析師的升級和降級</h2>
<p>多家研究公司對 RCKT 發表了評論。Chardan Capital 將 Rocket Pharmaceuticals 的股票目標價從 62.00 美元下調至 54.00 美元，並在 2 月 28 日（星期五）的研究報告中給予該股票 “買入” 評級。Jefferies Financial Group 在 12 月 18 日（星期三）的研究報告中開始覆蓋 Rocket Pharmaceuticals。他們給予該公司 “買入” 評級，並設定 29.00 美元的目標價。Canaccord Genuity Group 在 3 月 3 日（星期一）的研究報告中將 Rocket Pharmaceuticals 的目標價從 39.00 美元下調至 36.00 美元，並給予該公司 “買入” 評級。Needham &amp; Company LLC 在 4 月 9 日（星期三）的報告中重申了 “買入” 評級，並對 Rocket Pharmaceuticals 的股票設定 42.00 美元的目標價。最後，BMO Capital Markets 在 3 月 12 日（星期三）的研究報告中開始覆蓋 Rocket Pharmaceuticals。他們給予該公司 “跑贏大盤” 的評級，並設定 50.00 美元的目標價。一位分析師對該股票給予持有評級，十一位分析師給予該公司買入評級。根據 MarketBeat 的數據，該公司的平均評級為 “適度買入”，共識目標價為 43.00 美元。</p>
<p><strong>獲取我們對 Rocket Pharmaceuticals 的最新分析</strong></p>
<h2>關於 Rocket Pharmaceuticals</h2>
<p>（免費報告）</p>
<p>Rocket Pharmaceuticals, Inc 及其子公司作為一家晚期生物技術公司，專注於開發針對罕見和嚴重疾病的基因療法。它有三個臨牀階段的外源性慢病毒載體項目，針對範可尼貧血，這是一種骨髓中的遺傳缺陷，減少血細胞的產生或促進有缺陷血細胞的產生；白細胞粘附缺陷-I，這是一種導致免疫系統功能失常的遺傳疾病；以及丙酮酸激酶缺乏症，這是一種罕見的紅細胞常染色體隱性疾病，導致慢性非球形溶血性貧血。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Rocket Pharmaceuticals</li>
<li>標普 500 指數股票向投資者傳達了什麼市場信息？</li>
<li>當心 BigBear.ai：內部人士正在出售——你應該關注嗎？</li>
<li>消費者可選類股票解析</li>
<li>隨着網絡威脅環境的擴大，CrowdStrike 股票值得購買</li>
<li>哪些華爾街分析師的準確性最高？</li>
<li>國會！在關税引發的崩潰中，誰交易了什麼？</li>
</ul>
<p><strong>想看看其他對 RCKT 感興趣的對沖基金持有哪些股票嗎？</strong> 訪問 HoldingsChannel.com，獲取 Rocket Pharmaceuticals, Inc.（NASDAQ:RCKT - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資$1,000 在 Rocket Pharmaceuticals 嗎？</h2>
<p>在考慮 Rocket Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Rocket Pharmaceuticals 並不在名單上。</p>
<p>雖然 Rocket Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Rocket制藥

<p>根據 Synovus Financial Corp 最近向證券交易委員會提交的 13F 文件，該公司在 2023 年第四季度將其在 Rocket Pharmaceuticals, Inc.（NASDAQ:RCKT - 免費報告）中的持倉提高了 71.6%</p>

<p>Synovus Financial Corp lifted its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 71.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The firm owned 163,893 shares of the biotechnology company's stock after purchasing an additional 68,389 shares during the quarter. Synovus Financial Corp owned approximately 0.18% of Rocket Pharmaceuticals worth $2,060,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根據公司在最近向證券交易委員會提交的 13F 文件，Synovus Financial Corp 在第四季度將其在 Rocket Pharmaceuticals, Inc.（NASDAQ:RCKT - 免費報告）中的持倉提高了 71.6%。該公司在本季度購買了 68,389 股後，持有 163,893 股這家生物技術公司的股票。到最近一個季度末，Synovus Financial Corp 大約擁有 Rocket Pharmaceuticals 0.18% 的股份，價值 2,060,000 美元。</p>
</div><p>Get <strong>Rocket Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Rocket Pharmaceuticals</strong> 的提醒：</p>
</div><ul>
<li>3 Small-Cap Stocks That Are Ready to Rocket Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只准備大幅上漲的小型股</li>
</ul>
</div><p>Other large investors have also recently made changes to their positions in the company. Covestor Ltd lifted its stake in Rocket Pharmaceuticals by 33,166.7% in the fourth quarter. Covestor Ltd now owns 1,996 shares of the biotechnology company's stock valued at $25,000 after buying an additional 1,990 shares during the last quarter. Kennedy Capital Management LLC increased its holdings in shares of Rocket Pharmaceuticals by 222.6% in the 4th quarter. Kennedy Capital Management LLC now owns 38,208 shares of the biotechnology company's stock valued at $480,000 after acquiring an additional 26,365 shares during the period. Raymond James Financial Inc. purchased a new stake in Rocket Pharmaceuticals in the 4th quarter valued at $285,000. Renaissance Technologies LLC purchased a new stake in Rocket Pharmaceuticals in the 4th quarter valued at $2,747,000. Finally, Legal &amp; General Group Plc boosted its stake in Rocket Pharmaceuticals by 3.3% during the 4th quarter. Legal &amp; General Group Plc now owns 75,454 shares of the biotechnology company's stock worth $948,000 after purchasing an additional 2,416 shares during the period. 98.39% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他大型投資者最近也對該公司的持倉進行了調整。Covestor Ltd 在第四季度將其在 Rocket Pharmaceuticals 的股份提高了 33,166.7%。Covestor Ltd 現在擁有 1,996 股這家生物技術公司的股票，價值 25,000 美元，此前在上個季度又購買了 1,990 股。Kennedy Capital Management LLC 在第四季度將其在 Rocket Pharmaceuticals 的股份增加了 222.6%。Kennedy Capital Management LLC 現在擁有 38,208 股這家生物技術公司的股票，價值 480,000 美元，此前在此期間又收購了 26,365 股。Raymond James Financial Inc.在第四季度購買了 Rocket Pharmaceuticals 的新股份，價值 285,000 美元。Renaissance Technologies LLC 在第四季度購買了 Rocket Pharmaceuticals 的新股份，價值 2,747,000 美元。最後，Legal &amp; General Group Plc 在第四季度將其在 Rocket Pharmaceuticals 的股份提高了 3.3%。Legal &amp; General Group Plc 現在擁有 75,454 股這家生物技術公司的股票，價值 948,000 美元，此前在此期間又購買了 2,416 股。98.39% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Rocket Pharmaceuticals Trading Up 10.5 %</h2>
<div class="lb-trans"><h2>Rocket Pharmaceuticals 股價上漲 10.5%</h2>
</div><p>NASDAQ:RCKT opened at $6.53 on Wednesday. Rocket Pharmaceuticals, Inc. has a 1 year low of $4.55 and a 1 year high of $26.98. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.05. The stock has a fifty day moving average price of $8.19 and a two-hundred day moving average price of $11.92. The stock has a market capitalization of $696.29 million, a price-to-earnings ratio of -2.37 and a beta of 1.00.</p>
<div class="lb-trans"><p>NASDAQ:RCKT 週三開盤價為 6.53 美元。Rocket Pharmaceuticals, Inc.的 1 年最低價為 4.55 美元，1 年最高價為 26.98 美元。該公司的債務與股本比率為 0.06，速動比率為 6.05，流動比率為 6.05。該股票的 50 日移動平均價格為 8.19 美元，200 日移動平均價格為 11.92 美元。該股票的市值為 6.9629 億美元，市盈率為-2.37，貝塔係數為 1.00。</p>
</div><p>Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.06. As a group, sell-side analysts anticipate that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Rocket Pharmaceuticals（NASDAQ:RCKT - 獲取免費報告）最近在 3 月 3 日（星期一）發佈了季度財報。這家生物技術公司報告的每股收益為（0.62 美元），超過分析師一致預期的（0.68 美元）0.06 美元。作為一個整體，賣方分析師預計 Rocket Pharmaceuticals, Inc.在當前財年將發佈-2.83 的每股收益。</p>
</div><h2>Insider Buying and Selling at Rocket Pharmaceuticals</h2>
<div class="lb-trans"><h2>Rocket Pharmaceuticals 的內部買賣</h2>
</div><p>In other news, CEO Gaurav Shah bought 20,000 shares of the stock in a transaction on Thursday, April 10th. The shares were bought at an average price of $5.08 per share, with a total value of $101,600.00. Following the completion of the acquisition, the chief executive officer now owns 792,680 shares of the company's stock, valued at approximately $4,026,814.40. This trade represents a 2.59 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, insider Kinnari Patel purchased 21,099 shares of the business's stock in a transaction dated Wednesday, April 9th. The shares were purchased at an average cost of $4.70 per share, with a total value of $99,165.30. Following the purchase, the insider now directly owns 26,774 shares in the company, valued at approximately $125,837.80. The trade was a 371.79 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 28.50% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他消息中，首席執行官 Gaurav Shah 在 4 月 10 日（星期四）購買了 20,000 股該股票。每股購買價格為 5.08 美元，總價值為 101,600.00 美元。收購完成後，首席執行官現在擁有 792,680 股該公司的股票，價值約為 4,026,814.40 美元。這筆交易代表了他們持股比例的 2.59% 的增加。該收購在向證券交易委員會的文件中披露，相關信息可通過此鏈接獲取。此外，內部人士 Kinnari Patel 在 4 月 9 日（星期三）購買了 21,099 股該公司的股票。每股購買成本為 4.70 美元，總價值為 99,165.30 美元。購買後，該內部人士現在直接擁有 26,774 股該公司股票，價值約為 125,837.80 美元。這筆交易使他們的持股比例增加了 371.79%。該購買的披露信息可以在這裏找到。目前 28.50% 的股票由公司內部人士持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師的升級和降級</h2>
</div><p>A number of research firms have commented on RCKT. Chardan Capital dropped their price objective on shares of Rocket Pharmaceuticals from $62.00 to $54.00 and set a &#34;buy&#34; rating on the stock in a research note on Friday, February 28th. Jefferies Financial Group started coverage on Rocket Pharmaceuticals in a research note on Wednesday, December 18th. They set a &#34;buy&#34; rating and a $29.00 price objective for the company. Canaccord Genuity Group decreased their price objective on Rocket Pharmaceuticals from $39.00 to $36.00 and set a &#34;buy&#34; rating for the company in a research report on Monday, March 3rd. Needham &amp; Company LLC reissued a &#34;buy&#34; rating and issued a $42.00 target price on shares of Rocket Pharmaceuticals in a report on Wednesday, April 9th. Finally, BMO Capital Markets initiated coverage on Rocket Pharmaceuticals in a research note on Wednesday, March 12th. They set an &#34;outperform&#34; rating and a $50.00 price target for the company. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $43.00.</p>
<div class="lb-trans"><p>多家研究公司對 RCKT 發表了評論。Chardan Capital 將 Rocket Pharmaceuticals 的股票目標價從 62.00 美元下調至 54.00 美元，並在 2 月 28 日（星期五）的研究報告中給予該股票 “買入” 評級。Jefferies Financial Group 在 12 月 18 日（星期三）的研究報告中開始覆蓋 Rocket Pharmaceuticals。他們給予該公司 “買入” 評級，並設定 29.00 美元的目標價。Canaccord Genuity Group 在 3 月 3 日（星期一）的研究報告中將 Rocket Pharmaceuticals 的目標價從 39.00 美元下調至 36.00 美元，並給予該公司 “買入” 評級。Needham &amp; Company LLC 在 4 月 9 日（星期三）的報告中重申了 “買入” 評級，並對 Rocket Pharmaceuticals 的股票設定 42.00 美元的目標價。最後，BMO Capital Markets 在 3 月 12 日（星期三）的研究報告中開始覆蓋 Rocket Pharmaceuticals。他們給予該公司 “跑贏大盤” 的評級，並設定 50.00 美元的目標價。一位分析師對該股票給予持有評級，十一位分析師給予該公司買入評級。根據 MarketBeat 的數據，該公司的平均評級為 “適度買入”，共識目標價為 43.00 美元。</p>
</div><p><strong>Get Our Latest Analysis on Rocket Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 Rocket Pharmaceuticals 的最新分析</strong></p>
</div><h2>About Rocket Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Rocket Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.</p>
<div class="lb-trans"><p>Rocket Pharmaceuticals, Inc 及其子公司作為一家晚期生物技術公司，專注於開發針對罕見和嚴重疾病的基因療法。它有三個臨牀階段的外源性慢病毒載體項目，針對範可尼貧血，這是一種骨髓中的遺傳缺陷，減少血細胞的產生或促進有缺陷血細胞的產生；白細胞粘附缺陷-I，這是一種導致免疫系統功能失常的遺傳疾病；以及丙酮酸激酶缺乏症，這是一種罕見的紅細胞常染色體隱性疾病，導致慢性非球形溶血性貧血。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Rocket Pharmaceuticals</li>
<li>What Do S&amp;P 500 Stocks Tell Investors About the Market?</li>
<li>Beware of BigBear.ai: Insiders Are Selling—Should You?</li>
<li>Consumer Discretionary Stocks Explained</li>
<li>CrowdStrike Stock is a Buy as Cyberthreat Environment Expands</li>
<li>Which Wall Street Analysts are the Most Accurate?</li>
<li>Congress! Who Traded What During the Tariff-Induced Meltdown</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Rocket Pharmaceuticals</li>
<li>標普 500 指數股票向投資者傳達了什麼市場信息？</li>
<li>當心 BigBear.ai：內部人士正在出售——你應該關注嗎？</li>
<li>消費者可選類股票解析</li>
<li>隨着網絡威脅環境的擴大，CrowdStrike 股票值得購買</li>
<li>哪些華爾街分析師的準確性最高？</li>
<li>國會！在關税引發的崩潰中，誰交易了什麼？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding RCKT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 RCKT 感興趣的對沖基金持有哪些股票嗎？</strong> 訪問 HoldingsChannel.com，獲取 Rocket Pharmaceuticals, Inc.（NASDAQ:RCKT - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=RCKT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Rocket Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Rocket Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Rocket Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Rocket Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rocket Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Rocket Pharmaceuticals 並不在名單上。</p>
</div><p>While Rocket Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Rocket Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Acquired by Synovus Financial Corp

Rocket Pharmaceuticals, Inc.（納斯達克代碼：RCKT）的股份被 Synovus Financial Corp 收購